Mirion Technologies, Inc.: Radiation Detection Leader Poised for Defense & Nuclear Cycle

Mirion Technologies, Inc. designs, manufactures, and services radiation detection, measurement, analysis, and monitoring solutions. The company operates through two segments: (1) Radiation Safety & Security (~65% of revenue) — providing detection instruments, dosimetry services, and security screening for defense, homeland security, nuclear power, and industrial applications; and (2) Medical & Industrial (~35% of revenue) — offering imaging detectors for nuclear medicine, radiation therapy quality assurance, and industrial gauging solutions.

The company generates revenue through a hybrid model: ~55% from product sales (detectors, spectrometers, imaging systems) and ~45% from recurring services (calibration, maintenance, dosimetry badge processing, and software subscriptions). Customers include government agencies (U.S. Department of Defense, Department of Energy, allied militaries), nuclear utilities (over 200 plants globally), hospitals and cancer centers, and industrial manufacturers. Mirion has ~3,600 employees across 20 countries, with manufacturing hubs in the U.S., U.K., France, and Germany.

• Near-Term (FY2026-FY2027): Defense orders under the U.S. Army's CBRN sensor modernization program (a $250M multi-year contract awarded in Q1 2026) will ramp through 2027. We model 12% growth in the Radiation Safety & Security segment as international allies mirror U.S. procurement. Medical segment recovery is driven by hospital capital expenditure normalization — imaging detector replacement cycles, deferred during 2023-2025, are unlocking with 8% growth projected.
• Medium-Term (FY2028-FY2030): The SMR (small modular reactor) pipeline — with over 80 SMR projects announced globally by 2030 — requires radiation monitoring systems per reactor, representing a $400-500M addressable market for Mirion. Additionally, space radiation detection for satellite constellations and lunar missions (NASA Artemis and commercial programs) is an emerging growth vector, with Mirion supplying sensors for radiation-hardened electronics testing.

Revenue growth has been steady at 5-7%, but the composition is shifting favorably toward higher-margin services (now 45% of mix, up from 38% in FY2022), driving gross margin expansion of ~150 basis points over two years. GAAP EPS turned positive in FY2025 as amortization of acquisition-related intangibles ($45M annually) begins to taper — we model a step-change in EPS as this non-cash drag diminishes by FY2028. Free cash flow conversion is the key swing factor: inventory reduction initiatives and extended payment terms with suppliers should unlock $50-70M of working capital over the next two years.

The global radiation detection and monitoring market is valued at approximately $4.5B in 2026, growing at 7-8% CAGR through 2030, driven by nuclear power expansion, defense modernization, and medical imaging demand. Mirion holds an estimated 15-18% global market share, positioning it as the #2 player behind Thermo Fisher Scientific's environmental monitoring division (~20% share).

Mirion's competitive moat rests on its certified defense supply relationships (rare in this space) and its proprietary digital spectroscopy platform, which integrates hardware with AI-based isotope identification software — a capability competitors lack. The main competitive threat comes from Thermo Fisher's bundling of detection with broader lab services, but Mirion counters with specialized nuclear-grade certifications and faster custom engineering cycles.

DCF Analysis: We employ a 10-year discounted cash flow model with the following assumptions: FY2026-2030 revenue CAGR of 9.5%, terminal growth rate of 3.0%, and a WACC of 9.5% (reflecting beta of 1.05, 40% debt-to-capital ratio, and a 4.5% equity risk premium). Projected unlevered free cash flows (starting at $90M in FY2026 and growing to $220M by FY2030) yield a present value of ~$1.4B. Adding a terminal value of $3.2B (calculated using perpetuity growth method) and netting out net debt of $1.4B gives an equity value of ~$3.2B, or approximately $13.15 per share — implying the stock is fairly valued at current levels.

Comparable Company Multiples:

Mirion trades at a premium to diversified industrial peers on EV/EBITDA and P/E, reflecting its higher growth profile and defense exposure. However, on EV/Revenue, the stock is in line with Thermo Fisher, suggesting the market is pricing in margin convergence that has yet to materialize. The 19.28% short interest creates a squeeze risk that could drive the stock above our target, but also signals that institutional skepticism remains high on earnings quality.

• Defense Budget Cyclicality: ~40% of revenue is tied to government contracts, which face appropriations risk. A U.S. government shutdown or defense budget reallocation away from CBRN programs could cut FY2027 revenue by 5-8%.
• Integration & Operational Execution: The Silex merger integration is ongoing; further restructuring charges or supply chain disruptions in semiconductor-based detectors could delay the margin expansion timeline by 12-18 months.
• High Short Interest & Volatility: At 19.28% of float shorted, the stock is prone to violent moves either direction. Negative earnings surprises could trigger a short-covering rally, but sustained underperformance would validate bear thesis and pressure the stock toward the $14 low.
• Nuclear Incident or Regulatory Setback: Any major nuclear accident globally (e.g., Fukushima-style event) would trigger a temporary freeze in nuclear new-builds, reducing demand for Mirion's monitoring systems in the 2027-2028 timeframe.
• Interest Rate Sensitivity: With $1.4B in floating-rate debt, each 100bp increase in SOFR adds $14M in annual interest expense ($0.05/share), which could delay the EPS inflection we model.